Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of YN001 in Healthy Subjects
NCT05635084Phase 1Completed
- Sponsor
- Beijing Inno Medicine Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atherosclerosis comparing YN001 with Placebo (2 arms). Primary endpoint: Safety and tolerability of intravenously administered YN001. Started Dec 2022; status: completed.
02
Drugs
YN001
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT05635084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635084.